Pharmaceutical - Asia-Pacific, Bayer

Filter

Current filters:

Asia-PacificBayer

Popular Filters

1 to 25 of 31 results

Japanese approval for Bayer’s riociguat for CTEPH

Japanese approval for Bayer’s riociguat for CTEPH

20-01-2014

German pharma major Bayer has received approval from the Ministry of Health, Labor and Welfare for riociguat,…

AdempasAsia-PacificBayerPharmaceuticalRegulationRespiratory and Pulmonaryriociguat

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Should patients appreciate pharma?

Should patients appreciate pharma?

06-12-2013

Here's our take on the week's top stories.

Asia-PacificBayerEuropeFinancialHealthcareManagementPharmaceutical

Bayer files VEGF Trap-Eye for myopic choroidal neovascularization in Japan

Bayer files VEGF Trap-Eye for myopic choroidal neovascularization in Japan

29-11-2013

German drug major Bayer (BAYN: DE) has submitted VEGF Trap-Eye, already marketed under the brand name…

Asia-PacificBayerEyleaOphthalmicsPharmaceuticalRegeneronRegulationUSA

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Bayer joins string of drugmakers being investigated in China

16-09-2013

German pharma and crop sciences major Bayer (BAYN: DE) is being investigated in China over a "potential…

Asia-PacificBayerLegalMarkets & MarketingPharmaceutical

Bayer links with DKSH to expand in Singapore

10-09-2013

DKSH Business Unit Healthcare, a leading partner for health care companies seeking to grow their business…

Asia-PacificBayerMarkets & MarketingPharmaceutical

Bayer gets Japanese OK for GI stromal tumors drug

20-08-2013

German drug major Bayer (BAYN: DE) has received approval from the Ministry of Health, Labor and Welfare…

Asia-PacificBayerBiotechnologyOncologyPharmaceuticalRegulationStivarga

Indian patent appeal board upholds compulsory license on Bayer's Nexavar

05-03-2013

After much delay, the verdict into German pharmaceutical major Bayer's (BAYN: DE) appeal against the…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

Bayer files for Japanese approval of Eylea for macular edema following CRVO

07-01-2013

German drug major Bayer(BAYN: DE) says its subsidiary Bayer Yakuhin has applied to the Japanese Ministry…

afliberceptAsia-PacificBayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronRegulationSanten Pharmaceuticals

Nexavar use in Chinese patients nearly doubled in 2012

19-12-2012

Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

Access to many more medicines in Australia, as PBS list extended

28-10-2012

More than 110,000 Australians will benefit from better access to affordable medicines following the Australian…

Asia-PacificBayerEyleaMyforticNovartisPharmaceuticalPricingRegulation

India's IPAB rejects Bayer's "stay petition" regarding Nexavar

18-09-2012

Over the weekend, the Intellectual Property Appellate Board (IPAB) of Chennai, India, has dismissed the…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Bayer's regorafenib gets priority review for CRC in Japan

13-09-2012

Germany's Bayer (BAYN: DE) say that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted…

Asia-PacificBayerOncologyPharmaceuticalregorafenibRegulation

India's patent laws under pressure, say UK researchers

11-09-2012

In a special report in the prestigious medical journal The Lancet, researchers from Queen Mary, University…

Asia-PacificBayerEuropeGenericsLegalNovartisPatentsPharmaceutical

Bayer attempts to block generic Nexavar in India again slammed by MSF

04-09-2012

German drug major Bayer (BAYN: DE) yesterday headed to India's Intellectual Property Appellate Board…

Asia-PacificBayerGenericsLegalNexavarOncologyPatentsPharmaceutical

Indian hearings on Bayer Nexavar compulsory license delayed

22-08-2012

India's Intellectual Property Appellate Board (IPAB) in Chennai has postponed hearing the appeal by German…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Santen to co-promote Bayer and Regeneron's Eylea in Japan

09-05-2012

German drug major Bayer's (BAYN: DE) Japanese subsidiary, Bayer Yakuhin, and Santen Pharmaceutical (TYO:…

Asia-PacificBayerEyleaLicensingMarkets & MarketingOphthalmicsPharmaceuticalRegeneronSanten Pharmaceuticals

Bayer challenges Indian ruling on Nexavar patent

08-05-2012

German drug major Bayer (BAYN: DE) has launched an appeal against the Indian Patent Office, which a couple…

Asia-PacificBayerGenericsLegalNexavarOncologyPatentsPharmaceutical

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

1 to 25 of 31 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top